Author

Dana C. Borcherding

Washington University in St. LouisORCID 0000-0002-8849-2139Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

Angela C. HirbeiD· 2 shared Belinda B. GaranaiD· 2 shared Christine A. PratilasiD· 2 shared Sara J.C. GoslineiD· 2 shared Alex T. LarssoniD· 1 shared Chelsea M. Hutchinson-BunchiD· 1 shared David A. LargaespadaiD· 1 shared David K. WoodiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Angela C. HirbeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Integrated ex vivo screening and transcriptomic profiling to prioritize drug combinations for rare cancers

Ritu C. Shah, Alex T. Larsson, Belinda B. Garana, Yang Lyu, Zachary J. Seeman, Elizabeth Rono, Kyle Brandon Williams, Dana C. Borcherding, Ke Xiao, Xiaochun Zhang, Yannick Mahlich, Jeremy Jacobson, Lisa B. Fridman, Yan Zhou, Christine A. Pratilas, , Sara J.C. Gosline

The paper develops EXACT, a framework combining ex vivo drug screening with transcriptomic analysis to identify effective drug combinations for rare cancers, finding a MEK and HDAC inhibitor combination shows enhanced activity.

bioRxiv · Jul 29, 2026 · PreprintCancer Biology

Multi-omics integration of malignant peripheral nerve sheath tumors identifies potential targets based on chromosome 8q status

Belinda B. Garana, Jiawan JC Wang, Simge Acar, Gorkem Oztosun, Stavriani C. Makri, Dana C. Borcherding, Ying S. Zou, Chelsea M. Hutchinson-Bunch, Marina A. Gritsenko, Paul Piehowski, Christine A. Pratilas, Angela C. Hirbe, Sara J.C. Gosline

This study integrates multi-omics data from MPNSTs to identify drug targets based on chromosome 8q status, suggesting PLK1 and EGFR inhibitors could be effective in different subtypes.

bioRxiv · Jan 27, 2026 · PreprintCancer Biology